跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
13-a
首页
药物
13-a
13-a
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Interleukin-13 as a cardiovascular disease marker
申请人: UNIV SAGA
优先权: 2005
US
2 件公开
A DISINTEGRIN AND METALLOPROTEINASE WITH A THROMBOSPONDIN TYPE I MOTIF, MEMBER 13 (ADAMTS-13) MUTANTS, COMPOSITIONS AND THERAPEUTIC METHODS THEREOF
申请人: HADASIT MEDICAL RES SERVICES & DEVELOPMENT LIMITED
优先权: 2021
US
Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
申请人: GEM PHARMACEUTICALS LLC
优先权: 2006
CN
US
5 件公开
Methods and compositions including a 13 kD B. burgdorferi protein
申请人: SADZIENE ARIADNA
优先权: 2001
US
2 件公开
Antibacterial compound A-13, and application in preparing antibacterial drug
申请人: SHANGHAI HUMAN GENE GROUP RES
优先权: 2004
CN
13+/17+ BIN1 expression as a marker of cardiac disorders
申请人: SARCOTEIN DIAGNOSTICS LLC
优先权: 2016
US
Nano antibody SEA-4-13 for resisting staphylococcus aureus enterotoxin A and application of nano antibody SEA-4-13
申请人: UNIV NANCHANG
优先权: 2024
CN
Class A 12, 13-epoxy trichothecene compound, preparation method and application thereof
申请人: INST CHINESE MATERIA MEDICA CHINA ACADEMY OF CMS
优先权: 2025
CN
药物
反馈